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The current study investigated the action of 1,25-di-
hydroxyvitamin D3 (1,25D) at the genomic and signal
transduction levels to induce rat cytochrome P450C24
(CYP24) gene expression. A rat CYP24 promoter contain-
ing two vitamin D response elements and an Ets-1 bind-
ing site was used to characterize the mechanism of ac-
tions for the 1,25D secosteroid hormone. The Ets-1
binding site was determined to function cooperatively
with the most proximal vitamin D response element in a
hormone-dependent fashion. Evidence was obtained for
distinct roles of ERK1/ERK2 and ERK5 in the 1,25D-
inductive actions. Specifically, 1,25D stimulated the ac-
tivities of ERK1/ERK2 and ERK5 in a Ras-dependent
manner. Promoter induction was inhibited by mitogen-
activated protein (MAP) kinase inhibitors (PD98059 and
U0126) and a dominant-negative Ras mutant (Ras17N).
Induction of CYP24 by 1,25D was also inhibited by over-
expression of dominant-negative mutants of ERK1 and
MEK5 (ERK1K71R and MEK5(A)). The p38 and JNK
MAP kinases were not required for the action of 1,25D.
9-cis retinoid X receptor  (RXR) interacted with
ERK2 but not ERK5 in intact cells, whereas Ets-1 in-
teracted preferentially with ERK5. Increased phospho-
rylation of RXR and Ets-1 was detected in response to
1,25D. Activated ERK2 and ERK5 specifically phospho-
rylated RXR and Ets-1, respectively. Mutagenesis of
Ets-1 (T38A) reduced CYP24 promoter activity to levels
observed with the dominant-negative MEK5(A) and
inhibited ERK5-directed phosphorylation. Mutated
RXR (S260A) inhibited 1,25D-induced CYP24 pro-
moter activity and abolished phosphorylation by acti-
vated ERK2. The 1,25D-inductive action through ERK5
involved Ets-1 phosphorylation at threonine 38,
whereas hormone stimulation of ERK1/ERK2 required
RXR phosphorylation on serine 260. The ERK1/ERK2
and ERK5 modules provide a novel mechanism for
linking the rapid signal transduction and slower tran-
scription actions of 1,25D to induce CYP24 gene
expression.
The hormonally active form of vitamin D3 is 1,25-dihy-
droxyvitamin D3 (1,25D).
1 This secosteroid hormone plays a
central role in calcium homeostasis and bone metabolism and
participates in a diverse range of cellular actions including
inhibition of tumor cell growth, induction of cell differentiation,
and modulation of the immune response (1–4). The transcrip-
tional actions of 1,25D are mediated by the nuclear vitamin D
receptor (VDR), which heterodimerizes with retinoid X receptor
(RXR) and binds to specific vitamin D response element
(VDRE) sites in the promoter region of vitamin D-responsive
genes (5). Transactivation by the liganded VDR/RXR is depend-
ent upon the binding of one or more coactivator complexes that
permit bridging to the RNA polymerase II machinery (6, 7). In
the unliganded state, some nuclear receptors including VDR (8)
can bind a co-repressor that inhibits transactivation (9, 10), but
this repressor dissociates upon ligand binding.
Maintenance of cellular 1,25D levels is critical to regulation
of the function of the hormone in which high levels of 1,25D are
toxic and can lead to hypercalcemia and systems failure. There-
fore, a highly specific hydroxylase system functions within the
vitamin D pathway to tightly regulate control of 1,25D levels.
The mitochondrial hydroxylases cytochromes P450C1 and
P450C24 are responsible for the bioactivation and degradation
of vitamin D3 metabolites, respectively (11–13). Genes for the
hydroxylase enzymes are subject to stringent hormonal control,
most notably by 1,25D, which functions to down-regulate
P450C1 and up-regulate P450C24 enzyme expressions.
We are studying the molecular regulation of the P450C24
(CYP24) gene, which is expressed widely in different cell types
with the highest activity observed in kidney (1). CYP24 is a
multifunctional enzyme that directs the side-chain oxidation
and cleavage of 1,25D and 25D to catabolic carboxylic acid end
products (11, 13). The action of 1,25D to induce expression of
the rat CYP24 gene is mediated by two VDREs that are located
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about 100 bp apart within the 300-bp promoter region. The
synergistic action of the tandemly arranged VDREs underlies
the extraordinary high levels of induction that can be attained
in response to 1,25D and represents the most active vitamin
D-dependent promoter identified to date (14–16). The impor-
tant role for P450C24 gene expression has been further dem-
onstrated in CYP24 knockout mice in which null animals dem-
onstrated high ambient 1,25D levels and bone mineralization
defects (17).
During our studies into the molecular mechanism by which
1,25D induces CYP24 promoter activity, we identified an Ets-1
binding site located near the proximal VDRE that is important
for maximal transcriptional induction. Exogenously expressed
Ets-1 stimulated vitamin D induction, and this was further
enhanced by coexpression of Ras (18). Ras can elicit activation
of several downstream mitogen-activated protein (MAP)
kinases, among other signaling molecules (19–21), and in the
present study, we have asked whether vitamin D increases the
activities of MAP kinase pathways and whether these path-
ways impinge on the 1,25D-induced activation of the CYP24
promoter. Recent studies have indicated that 1,25D can elicit
rapid responses, apparently independent of gene expression
(22, 23). These non-genomic effects include changes in cera-
mide/phosphoinositide metabolism and increases in intracellu-
lar calcium as well as activation of protein kinase C (24).
Presumably these vitamin D-dependent responses are medi-
ated by a vitamin D receptor at the plasma membrane (25), but
the relationship of this putative receptor with that in the
nucleus remains obscure.
We provide evidence in the current study that vitamin D
directs the rapid activation of the MAP kinases ERK1/ERK2
and ERK5. Activation of RXR was obligatory to ERK1/ERK2,
whereas ERK5 was specifically required for Ets-1 phosphoryl-
ation. Inhibition of either the ERK1/ERK2 or ERK5 modules
substantially reduced vitamin D-induced transcriptional acti-
vation of the CYP24 promoter. Furthermore, simultaneous in-
hibition of both of these modules abrogated CYP24 promoter
activity induced by 1,25D, an effect that was mimicked by
inhibition of Ras function. Our results emphasize the critical
roles played by MAP kinase pathways in the phosphorylation of
Ets-1 and RXR during the 1,25D induction process.
EXPERIMENTAL PROCEDURES
Reagents—1,25D and 25D were purchased from Tetrionics, Inc.,
Madison, WI. The Dual-Luciferase Reporter Assay System (DLR) and
the anti-ACTIVETM ERK antibody were from Promega (Madison, WI),
and anti-HA and anti-ERK2 antibodies were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Monoclonal anti-phosphothreonine
and anti-phosphoserine antibodies were purchased from Sigma.
[-32P]ATP (specific activity, 4000 Ci/mmol) was obtained from Gene-
works (Adelaide, Australia). Myelin basic protein (MBP) was purchased
from Sigma. DOTAP was obtained from Roche Diagnostics. The follow-
ing inhibitors, SB203580, PD98059, and U0126, were purchased from
Biomol Research Laboratories (Plymouth Meeting, PA).
Promoter Luciferase Constructs and Expression Plasmids—CYP24
promoter luciferase constructs used in this study contain 298 bp of
CYP24 promoter sequence together with 74 bp of 5-untranslated region
in the pGL3 basic vector with the firefly luciferase reporter gene as
described previously (see Fig. 1) (18). The mutant constructs, pCYPm-
VDRE1(298)-Luc, pCYPmVDRE2(298)-Luc, and pCYPmVDRE1 
2(298)-Luc, have been described previously (18). VP16-VDR, pG5E1B-
Luc, pRSV-hVDR, and pRSV-hRXR constructs have been described
previously (9, 16, 18, 26). GAL4-Ets-1 was constructed by PCR ampli-
fication of human Ets-1 cDNA sequence using pEFBOS-Ets-1 as a
template (18) and two PCR primers engineered with an NdeI restriction
enzyme site. The PCR product was cloned at the NdeI site in the GAL4
vector (9). GAL4-Ets-1T38A and pRSV-hRXR S260A were created in
our laboratory by the QuikChange site-directed mutagenesis protocol
(Stratagene, La Jolla, CA). The dominant-negative Ras (Ras17N) and
dominant-negative ERK1 (ERK1K71R) have been described (27, 28).
The dominant-negative MEK5, MEK5(A), and HA-ERK5 constructs
were kindly provided by Dr E. Nishida (Kyoto University, Kyoto, Japan)
(29). GST-Ets-1 was provided by Professor Ismail Kola, and the GST-
Ets-1T38A mutant was constructed in our laboratory. Expression vec-
tors for GST-hRXR and GST-hVDR have been described previously
(18). The GST-tagged proteins were purified using glutathione-Sepha-
rose 4B (Qiagen, GmbH, Hilden, Germany). The MEKK-1 dominant-
negative and HA-ERK2 clones were kindly provided by Dr. David
Riches (Denver, CO) (30), and the MAP kinase phosphatase-1 (MKP-1)
overexpression clone has been described previously (31).
Maintenance and Transfection of Cells—Monkey kidney fibroblast
COS-1 cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum. In preparation for
transfection, cells were grown in a 75-cm2 flask to 60–70% confluency,
washed once with phosphate-buffered saline, and removed by
trypsinization. Cells (40,000/well) were seeded in a 24-well tray and
grown in 400 l of DMEM supplemented with 5% fetal calf serum. After
the cells were attached in the well (3–4 h), the medium was removed,
and the cells were washed once with phosphate-buffered saline, and
then the medium was replaced with serum-free RPMI medium. Cells
were incubated for 2 h for synchronization prior to transfection. For
each triplicate transfection, the CYP24 promoter luciferase construct
(600 ng) was mixed with 15 l of Hepes buffer (20 mM, pH 7.4) in an
Eppendorf tube with 600 ng of Ets-1 expression clone (pEFBos-Ets-1,
Ref. 18) or vector alone or the indicated amount of dominant-negative
expression clones together with 150 ng of pRL-TK as a control for
transfection efficiency. For most experiments, 600 ng of pRSV-hVDR
was also transfected to compensate for the low endogenous VDR level.
In all transfections, the final amount of DNA was kept constant by
addition of the appropriate vector plasmid. In another tube, 7.5 g of
DOTAP was diluted to 15 l in Hepes buffer and mixed with 15 l of
diluted DNA plasmids. After incubation for 10 min at room temperature
for DNADOTAP complex formation, 10 l of this DNADOTAP complex
was aliquoted into three wells of a 24-well plate. The following day, the
medium was replaced with 400 l of serum-free RPMI medium, and
cells were further cultured for 24 h in the presence of a specific kinase
inhibitor and/or 1,25D or ethanol carrier prior to harvesting. Dual
luciferase activity in cell lysates was determined by the DLR assay kit
using a luminometer model TD 20/20 (Turner Design Instruments,
Sunnyvale, CA).
Mammalian Two-hybrid Assay—Human choriocarcinoma cells,
JEG-3, were cultured for 24 h in DMEM containing 5% charcoal-
stripped fetal calf serum. Cells were cotransfected with 200 ng of
reporter plasmid (pG5E1b-Luc) and 50 ng of pRL-TK-Luc (transfection
efficiency control) with 500 ng each of GAL4-Ets-1 or GAL4-Ets-1T38A
plasmids with either VP16-TR or VP16-VDR expression plasmids using
the DOTAP transfection protocol as described earlier in this section.
After 24 h, medium was changed, and 1,25D was added as indicated.
Cells were further cultured for 24 h in serum-free DMEM and then
harvested for DLR assays.
Preparation of Cell Lysates—COS-1 cells with or without transfected
HA-tagged expression constructs (confluent 10-cm dishes) were stimu-
lated with 1,25D, H2O2, or phorbol 12-myristate 13-acetate for the
times indicated at 37 °C in a humidified atmosphere of 5% CO2 in air.
The incubations were terminated by removing the medium and wash-
ing the cells once with Hanks’ buffered salts solution (4 °C). The cells
were scraped and lysed in 200 l of buffer A (25 mM Tris/HCl, pH 7.5,
2 mM EGTA, 25 mM NaCl, 1 mM Na3VO4, 38 mM p-nitrophenyl phos-
phate, 10 g/ml each of pepstatin A, benzamidine, aprotinin, and leu-
peptin, 2 mM phenylmethylsulfonyl fluoride and 1 mM dithiothreitol) by
constant rotation for 2 h at 4 °C. Soluble fractions were collected after
centrifugation (16,000  g, 3 min, 4 °C), and the protein content of the
lysates was determined by Lowry’s method of protein determination.
Samples were stored at 70 °C until assayed. For Western blot analy-
sis, samples were mixed with Laemmli buffer and boiled before being
stored.
Immunoprecipitation—Lysates containing equal amounts of protein
were precleared with protein A-Sepharose (15 l) before being incu-
bated with anti-HA antibody (3 g of each) to immunoprecipitate
HA-ERK2, HA-ERK5, HA-RXR, or HA-Ets-1. The antigen-antibody
complexes were sedimented by the addition of protein A-Sepharose (15
l) and centrifugation (16,000  g for 20 s, 4 °C). The immune com-
plexes were washed (2  200 ml) with buffer A.
Kinase Assays—The immune complexes were washed with assay
buffer (1  200 l) (20 mM HEPES, pH 7.2, 20 mM glycerophosphate, 10
mM Sigma 104, 10 mM MgCl2, 1 mM dithiothreitol, 50 M orthovana-
date, 20 mM cold ATP), and kinase assays were started by the addition
of assay buffer (30 ml) containing 10 Ci of [-32P]ATP and MBP,
GST-RXR, GST-Ets-1, His-Ets-1, or GST-VDR (10–15 g/sample). In
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some assays, GST-tagged mutants of RXR or Ets-1 were used. After 20
min at 30 °C, the assays were terminated by the addition of Laemmli
buffer (15 ml), and the samples were boiled for 5 min. Phosphorylated
substrates were fractionated on 16% (MBP) or 10% (GST-tagged pro-
teins) SDS-PAGE gels and detected using an Instant Imager (Packard
Instruments, Canberra, Australia).
Western Blot Analysis—To determine the level of ERK1 and ERK2
dual phosphorylation, lysates containing equal amounts of denatured
proteins were subjected to SDS-PAGE (12% gels). After transfer to
nitrocellulose, the blot was probed with anti-ACTIVETM ERK antibody.
Immunoreactive bands were visualized by enhanced chemilumines-
cence (32). The blot was stripped using a Western blot recycling kit
(Alpha Diagnostic International, San Antonio, Texas) and reprobed
with anti-ERK2 antibody to confirm equal protein loading between
lanes. To detect co-immunoprecipitated proteins, immunoprecipitated
samples were subjected to Western blot analysis, and the blots were
probed first with one antibody, stripped, and reprobed with another
antibody as indicated under “Results.”
RESULTS
Stimulatory Action of Ets-1—The plasmid pCYP24WT(298)-
Luc contains 298 bp of rat CYP24 promoter sequence encompass-
ing the two known functional VDREs and the Ets-1 protein binding
site designated EBS (Fig. 1). We have previously shown that Ets-1
present in nuclear extracts of COS-1 cells binds EBS, whereas
exogenous Ets-1 can stimulate 1,25D induction of a truncated
CYP24 promoter containing only the first VDRE and the nearby
EBS (18). Initial studies were undertaken to evaluate the effect of
ectopically expressed wild type Ets-1 on 1,25D induction of the
298 bp CYP24 promoter. With hormone alone, a 4.8-fold level of
induction was observed, and overexpressed Ets-1 increased this to
11.2-fold (Fig. 2A). Endogenous VDR is limiting in these cells, and
exogenously expressed human VDR (hVDR) increased 1,25D in-
duction to 26-fold, whereas a combination of exogenous VDR and
Ets-1 further enhanced induction to 56-fold, the latter reflecting a
functional cooperation of these transcription factors. When the EBS
was inactivated (pCYP24mEBS(298)-Luc), the level of induction
by exogenous Ets-1 and VDR together was reduced to 14.0-fold
(Fig. 2A). Ets-1 alone did not alter basal promoter activity in the
absence of hormone (data not shown).
A mutant form of the wild type Ets-1 protein was examined
in which threonine residue 38 was mutated to alanine (Ets-1
T38A). This threonine residue is conserved in several Ets pro-
teins, and based on other work (31), it is likely to be phospho-
rylated in a Ras-dependent fashion, although the identity of
any specific MAP kinase involved is not known (33). The 26-fold
level of induction observed with exogenous VDR (Fig. 2A) was
lowered to 16-fold when the mutant Ets-1 T38A was overex-
pressed, a value comparable with that seen when the EBS was
mutated (Fig. 2A). This result shows that the expressed mutant
Ets-1 protein competes strongly with endogenous Ets proteins
for binding to EBS but is unable to functionally cooperate with
VDRRXR complexes on either VDRE-1 or VDRE-2 in response
to 1,25D. In control experiments, it was established that Ets-1
T38A did not alter basal expression of the construct (results not
shown), whereas mutagenesis of both VDREs abolished 1,25D
induction (Fig. 2A). These data demonstrate that wild type
Ets-1 substantially enhance vitamin D-induced promoter activ-
ity in the presence of two VDREs and that the threonine 38
residue of Ets-1 is vital for its functional cooperation with VDR
in the presence of 1,25D.
Experiments were undertaken to determine whether the
functional cooperation observed between exogenously ex-
pressed hVDR and Ets-1 occurred on one or both VDREs pres-
ent in the CYP24 promoter. As observed already, overex-
pression of hVDR alone gave a 26-fold level of induction with
pCYP24WT(298)-Luc, and this was increased to 56-fold with
coexpression of Ets-1 (Fig. 2B). There was no stimulatory effect
of overexpressing Ets-1 when VDRE-1 was mutated (Fig. 2B);
however, over-coexpression of Ets-1 and hVDR increased 1,25D
induction from 7.9- to 14.9-fold when analyzed in the presence
of inactive VDRE-2 (Fig. 2B). The results demonstrate that the
proximity of the EBS to VDRE-1 underlies its contribution to
induction. Evidence for an in vivo protein-protein interaction
between Ets-1 and VDR was achieved using the mammalian
two-hybrid assay and the plasmid G5E1B-Luc as reporter (Fig.
2C). The fusion protein GAL4-Ets-1 interacted substantially
with VP16-VDR but did not interact with control VP16-T3R
(Fig. 2C). A similar interaction was seen with GAL4-Ets-1T38A
(results not shown). VDR and wild type and mutant Ets-1
interactions were unaltered by 1,25D treatment (Fig. 2C). It is
evident from these experiments that the ligand-independent
interaction between Ets-1 and VDR does not require the thre-
onine 38 residue of Ets-1. In agreement with this observation,
it has been shown from in vitro pull-down experiments that a
region in the DNA binding domain of VDR interacts with an
Ets-1 deletion protein that lacks threonine 38 (34).
Suppression by Dominant-negative Ras and EBS Muta-
tions—We have previously shown that overexpression of H-Ras
in COS-1 cells increases 1,25D induction of the CYP24 pro-
moter construct and that this action is potentiated in the pres-
ence of the wild type but not the mutant form Ets-1 (18). This
implies that Ras plays a role in the 1,25D induction of the
CYP24 promoter in COS-1 cells and that Ets-1 can positively
modulate the action of Ras. To investigate the possible involve-
ment of endogenous Ras activity, we have overexpressed an
inhibitory dominant-negative ras construct, ras17N. Expres-
sion of Ras17N strongly reduced 1,25D induction of the
pCYP24WT(298)-Luc construct from 26- to 3.5-fold at the
highest concentration tested. At these concentrations of
Ras17N, there was no effect on basal expression of
pCYP24WT(298)-Luc or expression of the internal control
pRL-TK-Luc described under “Experimental Procedures” (data
not shown), demonstrating that Ras17N has a selective inhib-
itory effect on 1,25D induction. However, in the absence of
Ras17N, mutagenesis of the EBS reduced 1,25D induction to
14.0-fold (Fig. 3). These results not only demonstrate that Ras
is essential for components of the 1,25D-responsive transcrip-
tion machinery but also suggest that although the EBS is a
downstream mediator site of Ras signaling, the action of Ras is
also channeled through other downstream effectors.
Activation of ERK1/ERK2 and ERK5 by 1,25D—The extra-
cellular signal-regulated protein kinase ERK1/ERK2 MAP
FIG. 1. Schematic of wild type pCYP24WT(298)-luciferase reporter construct. Relative locations of the VDRE-1 and VDRE-2 and EBS
located on the antisense strand of the rat cytochrome P450C24 (CYP24) promoter are shown. The construct contains 298 bp of promoter sequence
together with 74 bp of 5 untranslated region.
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kinases are major downstream effectors of Ras. Both MAP
kinases are members of a cascade of kinases that consists of the
MAP kinase kinase kinase, raf-1, which phosphorylates and
activates the MAP kinase kinases, MEK1/MEK2, the immedi-
ate upstream regulators of ERK1/ERK2 (20). To determine
whether ERK1/ERK2 are involved in the actions of 1,25D, we
first investigated whether 1,25D-stimulated the activities of
ERK1/ERK2 in COS-1 cells. It is evident from the data in Fig.
4A that 1,25D at 107 M rapidly increased ERK1/ERK2 dual
phosphorylation and hence activity. Although increased ERK1
phosphorylation persisted for at least 30 min, ERK2 phospho-
rylation peaked at 5 min after the addition of 1,25D. The effect
of 1,25D on ERK1/ERK2 dual phosphorylation was also ob-
served at 109 but not at 1010 M (Fig. 4B). The precursor, 25D,
COS-1 cells together with expression clones for Ets-1 and Ets-1T38A as
indicated. To compensate for low endogenous VDR, human VDR (pRSV-
hVDR) was cotransfected in all experiments. As an internal control for
correction of transfection efficiency, cells were also transfected with
pRL-TK-Luc (see “Experimental Procedures”). Each construct was
tested for 1,25D (107 M) transactivation, and the level of induction
(Fold 1,25D induction) is shown as the ratio of luciferase activity from
1,25D-treated cells to that of untreated cells. The data presented here
are the averages of three independent experiments  S.D. B, Ets-1
stimulates 1,25D-dependent transactivation of the CYP24 promoter
through VDRE-1. pCYP24WT(298)-Luc, pCYP24mVDRE-1(298)-
Luc, or pCYP24mVDRE2(298)-Luc constructs were cotransfected into
COS-1 cells together with pRSV-hVDR (not shown). The promoter con-
structs were tested for 1,25D transactivation (as in panel A) in the
presence () or absence () of overexpressed Ets-1. The data presented
here are the averages of three independent experiments  S.D. C,
protein-protein interaction of Ets-1 with VDR in the mammalian two-
hybrid assay. Human choriocarcinoma cells (JEG-3 cells) were cotrans-
fected with 500 ng of GAL4-Ets-1 chimera and 500 ng of VP16 vector
(VP16 (0)) or VP16-VDR or VP16-T3R chimera as indicated together
with 200 ng of pG5E1B-Luc reporter with 50 ng of pRL-TK-Luc as an
internal control. Cells were also treated with 1,25D (107 M) as indi-
cated. The luciferase activity of GAL4-Ets-1 in the presence of VP16
vector is arbitrarily set to 100%, and activities are expressed relative to
this as percent of expression. The data presented here are the averages
of three independent experiments  S.D.
FIG. 2. Role of Ets-1 in CYP24 promoter function. A, effect of
Ets-1 on 1,25D-dependent transactivation of CYP24 promoter-lucif-
erase constructs. pCYP24WT(298)-Luc, pCYP24mEBS(298)-Luc, or
pCYP24mVDRE1  2(298)-Luc constructs were cotransfected into
FIG. 3. Inhibition of 1,25D-dependent transactivation of
CYP24 promoter-luciferase constructs by the ras dominant-
negative construct, ras17N. pCYP24WT(298)-Luc, pCYP24-
mEBS(298)-Luc, or pRSVhVDR (not shown) were cotransfected in
COS-1 cells together with increasing doses of ras17N expression clone
(100–500 ng). The promoter constructs were tested for 1,25D trans-
activation (as in panel A of Fig. 2). The data presented here are the
averages of three independent experiments  S.D.
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at 107 M did not affect ERK1/ERK2 phosphorylation (Fig. 4B)
nor induce pCYP24WT(298)-Luc expression (data not shown)
in which stimulation of MAP kinase was selective for 1,25D at
a low concentration. Activation of ERK2 activity by 1,25D using
myelin basic protein as a substrate was confirmed in cells that
had been transfected with HA-ERK2 (Fig. 4C). Co-transfection
of the cells with ras17N reduced but did not abolish 1,25D-
stimulated ERK2 activation (Fig. 4C). These data demonstrate
that 1,25D stimulates the Ras-ERK1/ERK2 cascade in COS-1
cells. Recently the activity of another MAP kinase, ERK5, was
reported to be regulated by Ras (35). The upstream regulators
in the ERK5 cascade consist of the MAP kinase kinase, MEK5,
and the MAP kinase kinase kinases, MEKK3 and Cot (36–38).
In a parallel manner, 1,25D also substantially stimulated HA-
ERK5 activity after exposure of the cells to 1,25D for at least 10
min (Fig. 4D). Consistent with ERK5 being a stress-activated
kinase (36), its activity was up-regulated by H2O2 (Fig. 4D).
This is in contrast to the lack of effect of H2O2 on ERK1/ERK2
dual phosphorylation (Fig. 4A). The ability of 1,25D to stimu-
late ERK5 activity was essentially abrogated by Ras17N (Fig.
4E). As has been observed for ERK1/ERK2 dual phosphoryla-
tion, ERK5 activity was stimulated by 107 and 109 M 1,25D,
whereas kinase activity was only marginally stimulated by
1010 M (Fig. 4F). 25D at 107 M did not affect ERK5 activity
(Fig. 4F). In these assays, basal ERK1/ERK2 and ERK5 phos-
phorylation and/or activities were detectable in unstimulated
cells. In other experiments (data not shown), we observed
that 1,25D at concentrations as low 1010 M was able to
activate pCYP24WT (298)-Luc, but 25D failed to activate
even at 107 M.
Involvement of the ERK1/ERK2 and ERK5 Pathways—The
above data raise the possibility that ERK1/ERK2 and ERK5
could be involved in the regulation of CYP24 promoter induc-
tion by 1,25D. Preincubation of COS-1 cells with PD98059, an
inhibitor of MEK1/MEK2 and MEK5 and thereby the respec-
tive ERK1/ERK2 and ERK5 modules (29), severely inhibited
1,25D induction of CYP24 promoter activity when tested at 10
M and almost abolished induction at 100 M (Fig. 5A). The
inhibitor U0126, which inhibits MEK1/MEK2 and MEK5, also
markedly suppressed 1,25D induction, although not to the level
observed for PD98059 (Fig. 5A). Furthermore, overexpression
of the dual specificity MAP kinase phosphatase MKP-1 (31)
was highly effective in blocking 1,25D induction (Fig. 5A). In
contrast, neither SB203580 (10 M), an inhibitor of p38, -,
and -, nor the inhibitory dominant-negative mutant of
MEKK1 (DN-MEKK1), a MAP kinase kinase kinase of the JNK
cascade, affected 1,25D induction of the pCYP24WT(298)-Luc
construct (Fig. 5A). In these experiments, the chemical inhibi-
tors and dominant-negative mutant at the concentrations used
did not alter basal expression of pCYP24WT(298)-Luc or
pRL-TK-Luc (results not shown), demonstrating specificity in
their inhibitory actions. From these data, we conclude that
either the ERK1/ERK2 or ERK5 modules or both, but not p38
or JNK modules, mediate the 1,25D induction of the CYP24
promoter in COS-1 cells. We investigated whether these re-
quirements for 1,25D induction are unique to the CYP24 pro-
moter in these cells. The effects of the pharmacological inhib-
itors were determined on the expression of a plasmid
FIG. 4. Activation of ERK1/ERK2 by 1,25D. A, time-dependent
stimulation of ERK1/ERK2 activities by 1,25D. COS-1 cells were stim-
ulated with positive control phorbol 12-myristate 13-acetate (PMA,
107 M), negative control H2O2 (10
3 M), or 1,25D (107 M) for 5, 5, and
1–30 min, respectively. Ethanol solvent only is shown as C. The cells
were lysed, and the dual phosphorylation of ERK1/ERK2 was deter-
mined by Western blot (WB) analysis using an anti-active ERK anti-
body (WB:ACTIVE ERK). Unphosphorylated ERK2 was detected us-
ing anti-ERK2 antibody (WB:ERK2). B, effect of 25D and 1,25D
concentrations on ERK1/ERK2 activities. COS-1 cells were stimulated
with 25D (107 M) or 1,25D (1010-107 M) for 5 min and then lysed, and
the dual phosphorylation of ERK1/ERK2 was determined as described
in panel A. C, effect of Ras17N on 1,25D stimulation of ERK2 activity.
COS-1 cells were transfected with HA-ERK2 or cotransfected with this
plasmid and ras17N. After stimulation with 1,25D (107 M) for 5 min,
the cells were lysed, and HA-ERK2 was immunoprecipitated. Kinase
activity was determined using MBP as a substrate, and the results were
quantitated using an Instant Imager. D, time-dependent stimulation of
HA-ERK5 activity. COS-1 cells were transfected with HA-ERK5 and
stimulated with H202 (15 min) or 1,25D (10
7 M) for 2–30 min. After
lysis, the activity of immunoprecipitated HA-ERK5 was determined
using MBP as a substrate. E, effect of Ras17N on stimulation of HA-
ERK5. COS-1 cells were transfected with HA-ERK5 or cotransfected
with this plasmid and ras17N. After stimulation (15 min), the cells were
lysed, and immunoprecipitated HA-ERK5 activity was determined as
described above. F, effect of 25D and 1,25D concentrations on HA-ERK5
activity. COS-1 cells were transfected with HA-ERK5 and stimulated
with 25D (107 M) or 1,25D (1010-107 M) for 5 min, and kinase activity
was determined as described above. Results are representative of three
to five experiments.
Role of ERKs in CYP24 Promoter Induction 29647
FIG. 5. Involvement of ERK1/ERK2 and ERK5 pathways. A, effect of specific MAP kinase pathway inhibitors, dominant negatives, and MAP
kinase phosphatase on transactivation. The pCYP24WT(298)-Luc construct was analyzed for its 1,25D-mediated transactivation, as in panel A
of Fig. 2, in the presence of the MEK inhibitors (PD98059 or U0126), the p38 inhibitor (SB203580), the dominant-negative MEKK1 (DN-MEKK1),
or MKP-1. B, roles of specific MAP kinase pathways in the action of VDR. A consensus DR3-type VDRE sequence attached to the thymidine kinase
promoter (DR3TK-Luc) was analyzed in the presence of the MEK inhibitors (PD98059 or U0126), the p38 inhibitor (SB203580), as described in
panel A above. The data were presented as relative luciferase activity (RLA). The data presented here are the averages of three independent
experiments  S.D. C, mediation of ERK1/ERK2 and ERK5 functions through EBS. The effect of 1,25D-mediated transactivation was analyzed,
as in panel A of Fig. 2, on pCYP24WT(298)-Luc and pCYP24mEBS(298)-Luc constructs in the presence of the dominant-negative ERK1 (ERK1
K71R) and the dominant-negative MEK5 (MEK5(A)) constructs. D, roles of ERK1/ERK2 and ERK5 in the action of VDR. A consensus DR3-type
VDRE sequence attached to thymidine-kinase promoter sequence (DR3TK-Luc) was analyzed in the presence of ERK1K71R or MEK5(A) as
described above. The data were presented as relative luciferase activity (RLA). The data presented here are the averages of three independent
experiments  S.D. Fold 1,25D induction for panels A and C was calculated as in panel A of Fig. 2. The data presented here are the averages
of three independent experiments  S.D.
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containing a DR3-type VDRE fused to the TK promoter (pDR3-
TK-Luc) and the same plasmid lacking the VDRE (pTK-Luc)
(Fig. 5B). 1,25D induced expression of pDR3-TK-Luc by about
2-fold, and this was inhibited by PD98059 and U0126 but not
by SB203580. By contrast, these inhibitors did not affect ex-
pression of the pTK-Luc construct (Fig. 5B). In these experi-
ments, lowered basal expression of pDR3-TK-Luc as compared
with pTK-Luc was seen as observed previously and attributed
to binding of a repressor to the VDRE in the absence of 1,25D
(9). The data show that the requirement for ERK1/ERK2
and/or ERK5 pathways for 1,25D induction is not CYP24
promoter-specific.
To further evaluate the contributions of the ERK1/ERK2 and
ERK5 modules to 1,25D induction of the CYP24 and TK pro-
moter constructs, cells were transiently transfected with the
dominant-negative mutant of ERK1 and MEK5, ERK1K71R
and MEK5(A), respectively. ERK1K71R, which blocks the ac-
tion of ERK1 and ERK2 (27), lowered 1,25D-induced CYP24
promoter activity by about 80% (Fig. 5C). It is evident from
these data and the results in Fig. 4 that the activity of the
ERK1/ERK2 module is stimulated by 1,25D and also that the
ERK1/ERK2 module constitutes a signaling pathway that is
required for the induction of CYP24 promoter activity by the
hormone. MEK5(A), a specific inhibitory dominant-negative
construct of the ERK5 pathway (29), reduced promoter activity
by about 40% (Fig. 5C). The magnitude of this effect was
similar to that caused by the EBS mutant promoter construct
(Fig. 5C). The lowered 1,25D-inductive action observed for the
EBS mutation was further reduced by ERK1K71R, but no
further inhibition of the mutated EBS promoter construct was
observed in the presence of the MEK5 inhibitory dominant-
negative construct MEK5(A) (Fig. 5C). This latter finding is
significant and establishes that ERK5 activity is specifically
required for functionality of the EBS binding protein. In con-
trast, ERK1/ERK2 must be required for the phosphorylation
and activation of other components of the induction machinery,
which represent the principal signaling pathway in the induc-
tion process. In keeping with this concept, the MEK5 domi-
nant-negative construct MEK5(A) did not further inhibit the
1,25D-inductive action in the presence of ERK1K71R (Fig. 5C).
It is relevant that ERK1K71R, but not MEK5A, abolished
1,25D induction from the pDR3TK-Luc construct, which lacks
the EBS (Fig. 5D). There was no effect of either ERK1K71R or
MEK5A on expression of pTK-Luc, which also lacks both an
EBS and a VDRE (Fig. 5D). Overall these results support the
contention that the ERK1/ERK2 module is crucial in COS-1
cells for the 1,25D induction process, whereas ERK5 plays a
more selective role in activating the EBS-stimulatory pathway.
Phosphorylation of RXR by HA-ERK2—Possible ERK1/
ERK2 substrates that are required for 1,25D induction of the
CYP24 promoter induction include RXR, VDR, and coactiva-
tor complex components such as SRC-1. Consensus MAP
kinase sites have been identified in SRC-1 (39) and RXR but
not in VDR (40). In Ras-transformed keratinocytes, phospho-
rylation of RXR at serine 260, which is within one of the two
MAP kinase consensus sites, results in a non-functional
VDRRXR complex (40). However, the identity of the MAP
kinase that phosphorylated this residue was not determined
(40). We transfected COS-1 cells, therefore, with wild type
RXR or the mutant, RXR S260A, in which the serine residue
was replaced with alanine (Fig. 6A). Induction of the CYP24
promoter by 1,25D was not influenced by overexpression of wild
type RXR (presumably reflecting high endogenous levels of
RXR). In contrast, the mutant RXRS260A inhibited 1,25D-di-
rected induction, which was an unexpected finding based on a
previous study (40) in which the mutation prompted an enhanced
1,25D action. These results suggest that phosphorylation of
RXR at serine 260 is required for RXR functionality during
1,25D induction of the CYP24 promoter in COS-1 cells. When
another potential MAP kinase site in RXR was mutated (threo-
nine 82 to alanine), the expression of this mutant had no effect on
1,25D induction of the CYP24 promoter construct (data not
shown).
To investigate whether ERK1/ERK2 phosphorylated RXR,
COS-1 cells were transfected with HA-ERK2, and the cells
were stimulated with 1,25D. The data in Fig. 6B demonstrate
that HA-ERK2 immunoprecipitated from these cells phospho-
rylated wild type GST-RXR. In contrast, parallel experiments
using HA-ERK5-transfected cells showed that HA-ERK5 im-
munoprecipitated from 1,25D-stimulated cells failed to phos-
phorylate GST-RXR (Fig. 6B). These results demonstrate sub-
strate specificity for ERK2 and ERK5. The ability of activated
HA-ERK2 to phosphorylate GST-RXR was substantially re-
duced when serine 260 in RXR was replaced with alanine
(GST-RXRS260A) (Fig. 6C). Hence, ERK2 activated by 1,25D
can phosphorylate RXR at serine 260. As expected, neither
HA-ERK2 nor HA-ERK5 phosphorylated GST-VDR (Fig. 6D).
Thus, VDR is not a substrate for either ERK2 or ERK5.
Interaction of RXR with ERK2 but Not with ERK5 and
Serine Phosphorylation of RXR—Although the above observa-
tions demonstrate the selective action of ERK1/ERK2, it is not
clear whether endogenous RXR is phosphorylated in 1,25D-
stimulated COS-1 cells and whether ERK1/ERK2 is involved in
phosphorylating RXR. To address this, COS-1 cells were
transfected with HA-RXR and stimulated with 1,25D. After
lysis, the samples were subjected to immunoprecipitation with
anti-HA antibody followed by Western blot analysis. The data
in Fig. 7A demonstrate that ERK2 but not ERK5 co-immuno-
precipitated with HA-RXR, implying an interaction between
ERK2 and RXR. This interaction was not dependent on 1,25D
(Fig. 7A). However, 1,25D increased the level of serine phos-
phorylation of RXR that was prevented by the dominant-
negative ERK1K71R and not observed with the mutant HA-
RXRS260A construct (Fig. 7B).
Interaction of Ets-1 with ERK5 and Threonine Phosphoryla-
tion of Ets-1—Suppressed 1,25D induction of CYP24 promoter
activity by the inhibitory dominant-negative mutant MEK5(A)
was not further inhibited by an EBS mutation, which implies
that the MEK5-ERK5 module may target Ets-1 in a linear
signaling pathway. To investigate this possibility, COS-1 cells
were transfected with HA-Ets-1 and stimulated with 1,25D.
After lysis, HA-Ets-1 was immunoprecipitated, and the sam-
ples were subjected to Western blot analysis. It is evident from
the data in Fig. 8A that ERK5 interacted with Ets-1 in a
1,25D-dependent manner. Although ERK5 did not interact
with Ets-1 in unstimulated cells, a weak interaction could be
observed at 2 h, and strong interaction was clearly observed at
24 h (Fig. 8A, upper panel). A weak interaction between Ets-1
and ERK2 was also detectable, but this was not affected by
1,25D (Fig. 8A, bottom panel). Treatment of the cells with
1,25D caused a gradual increase in the level of threonine phos-
phorylation of Ets-1, detectable at 2 h and increasing over a
24-h incubation period (Fig. 8B, bottom panel). In addition, in
vivo labeling experiments using 32Pi revealed a 1.8-fold in-
crease in Ets-1 phosphorylation in 1,25D-treated cells when
examined after 4 h (data not shown).
Phosphorylation of Ets-1 by HA-ERK5—The possibility that
the MEK5-ERK5 module may target Ets-1 in a linear signaling
pathway and that Ets-1 is a substrate for ERK5 was investi-
gated further using in vitro kinase assays. The HA-ERK5 that
was immunoprecipitated from 1,25D-stimulated cells phospho-
rylated His-Ets-1 in a manner that was dependent upon Ras
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and MEK5 (Fig. 9A). In contrast, HA-ERK2 immunoprecipi-
tated from the lysate of 1,25D-stimulated cells failed to phos-
phorylate His-Ets-1 (Fig. 9A). The ability of Ets-1 to function as
a phosphorylation target for ERK5 was greatly reduced by
substituting threonine 38 for alanine in GST-Ets-1-T38A (Fig.
9B), suggesting that threonine 38 of Ets-1 is a specific target for
ERK5.
DISCUSSION
Ets-1 plays a significant role in the up-regulation of CYP24
promoter activity. The Ets binding site (EBS) in the rat CYP24
promoter cooperates transcriptionally with VDRE-1 but not
with VDRE-2, presumably reflecting the close proximity of the
VDRE-1 and EBS (see Fig. 1). Indeed, direct in vivo protein-
protein interaction between Ets-1 and VDR was demonstrated
in the current study by the mammalian two-hybrid assay and
recently by an in vitro GST-protein pull-down study (34). It is
known that the proximal VDRE-1 is employed preferentially at
low 1,25D concentrations, whereas both VDREs are utilized at
high concentrations in a synergistic manner, providing the
promoter with the flexibility to respond to both low and poten-
tially toxic levels of hormone (16). Thus, the functional cooper-
ation between the EBS and VDRE-1 that is established in the
present study is likely to play an important role in facilitating
efficient transcription of the CYP24 gene across a broad range
of 1,25D levels.
The signaling mechanisms that regulate the 1,25D-mediated
transcriptional activation of the CYP24 promoter are poorly
defined. We previously suggested that Ras could play a role in
regulating the induction of CYP24 by 1,25D since overexpres-
sion of Ras enhanced hormone-stimulated CYP24 promoter
activity (18). The data presented here establish for the first
time that Ras and the downstream MAP kinase pathways
ERK1/ERK2 and ERK5 are critical for induction of the CYP24
promoter in response to 1,25D in COS-1 cells. The involvement
of Ras and ERK pathways was inferred from CYP24 promoter
expression studies using pharmacological antagonists and spe-
cific inhibitory dominant-negative mutants coupled with the
demonstration that 1,25D stimulated the activities of ERK1/
ERK2 and ERK5 in a Ras-dependent manner. ERK5 was ob-
served to act specifically through the EBS. However, ERK1/
ERK2 was observed to function at one or more locations other
than the EBS since the ERK1 dominant-negative mutant
ERK1K71R severely inhibited induction of the promoter con-
struct beyond the inactivation observed for a mutated EBS.
Furthermore the observation that ERK1K71R, but not the
MEK5 inhibitor MEK5(A), abolished induction of the artificial
TK-VDRE promoter construct (i.e. no EBS) strongly implicates
an ERK1/ERK2-dependent phosphorylation step that involves
the VDRE and is vital in the 1,25D induction mechanism.
Neither the JNK nor the p38 modules contributed to CYP24
induction in these cells.
The identification of Ets-1 as a substrate of ERK5 adds to the
list of transcription factors that are substrates of ERK5. Pre-
vious studies have demonstrated that ERK5 phosphorylates
c-Myc, Sap1a, and members of the MEF2 family of transcrip-
tion factors such as MEF2C (29, 36, 41). ERK5 has also been
FIG. 6. Phosphorylation of RXR by HA-ERK2. A, effect of
pRSV-hRXR S260A on 1,25D induction of CYP24 promoter.
pCYP24WT(298)-Luc, pRSVhVDR, pRSVhRXR, or pRSVhRXR
S260A were cotransfected in COS-1 cells as indicated. Fold 1,25D
induction was calculated as in panel A of Fig. 2. The data presented
here are the averages of three independent experiments  S.D. B,
phosphorylation of GST-RXR by HA-ERK2 and HA-ERK5. For kinase
activity assays, cells were transfected with HA-ERK2 or HA-ERK5 and
stimulated with 1,25D as described in the legend for Fig. 4. The sub-
strate was GST-hRXR. C, phosphorylation of GST-hRXR S260A by
HA-ERK2. As in panel B, with GST-hRXR or GST-hRXR S260A
as substrates. D, phosphorylation of GST-VDR by HA-ERK2 and
HA-ERK5. As in panel B, with GST-VDR as substrate. All results are
representative of three experiments.
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reported to be involved in regulating the expression of tumor
necrosis factor  in mast cells, although the mechanisms
through which ERK5 achieved this were not investigated (42).
Ets-1 contains a consensus MAP kinase phosphorylation site at
threonine 38 (33), and mutagenesis of the threonine residue to
alanine severely abrogated the transcriptional cooperation be-
tween EBS and VDRE-1 in response to 1,25D (18). In view of
the importance of threonine 38 in Ets-1 function, it is signifi-
cant that mutagenesis of threonine 38 also abolished the ability
of activated HA-ERK5 to phosphorylate this substrate. This
observation establishes that ERK5 phosphorylates Ets-1 on
threonine 38, and the phosphorylation of this residue has a
functional role in facilitating the transcriptional cooperation
between EBS and VDRE-1. Our finding that expression of the
MEK5 dominant-negative MEK5(A) inhibited ERK5 activation
and CYP24 promoter activity is consistent with the concept
that the ERK5 module couples the action of 1,25D-liganded
VDR to the EBS via Ets-1. This is reinforced by our demon-
stration in intact cells that 1,25D not only caused an increase
in the threonine phosphorylation of Ets-1 but that it also pro-
moted the binding of ERK5 to Ets-1. In contrast, 1,25D did not
have any impact on the weak but detectable interaction be-
tween ERK2 and Ets-1. An interaction between ERK2 and
Ets-1 is perhaps not surprising because Ets-1 has an LXL
ERK2 docking site C-terminal to the threonine 38 MAP kinase
phosphoacceptor. In contrast to the recent demonstration that
Ets-1 is a substrate for bacterially expressed ERK2 in cell-free
assays (43), it is apparent from our data that ERK2 immuno-
precipitated from 1,25D-stimulated cells did not phosphorylate
Ets-1. Suggested from this apparent discrepancy is the possi-
bility that ERK2 expressed and activated in mammalian cells
(our study) behaves differently from recombinant enzyme that
is expressed and activated in bacteria (43).
Our demonstration that ERK5 did not interact with RXR in
intact cells could account for the inability of 1,25D-activated
HA-ERK5 to phosphorylate RXR in in vitro kinase assays
despite the presence of two MAP kinase phosphoacceptor sites
(i.e. threonine 82 and serine 260 on RXR) (40). It would
appear, therefore, that RXR could lack an appropriate ERK5
docking site. On the other hand, 1,25D clearly activated the
HA-ERK2 phosphorylation of RXR. Investigations in intact
FIG. 7. Interaction of RXR with ERK2 and serine phosphoryl-
ation of RXR. A, interaction of RXR with ERK2 in intact cells. COS-1
cells were transfected with HA-RXR and incubated with 1,25D (107
M) for 0.5–24 h or solvent only (C). After lysis, HA-RXR was immuno-
precipitated with an anti-HA antibody and Western blotted (WB) to
detect the presence of co-immunoprecipitated ERK2. Blots were
stripped to enable reprobing with ERK5 antibody. The presence of
RXR was confirmed by probing the blots with an anti-HA antibody. B,
anti-phosphoserine antibody detection of phosphorylated RXR. COS-1
cells were cotransfected with HA-RXR and ERK1K71R or HA-
RXRS260A before being stimulated with 1,25D (2 h), and after lysis,
cells were immunoprecipitated with an anti-HA antibody and Western
blotted for the presence of RXR, and then blots were stripped and
reprobed with an anti-phosphoserine antibody to determine the level of
RXR phosphorylation. Results are representative of two (panel A) or
three (panel B) experiments.
FIG. 8. Interaction of Ets-1 with ERK5 and threonine phospho-
rylation of Ets-1. A, 1,25D-dependent interaction of ERK5 with Ets-1.
COS-1 cells were transfected with HA-Ets-1 and incubated with 1,25D
(107 M) for 2–24 h or with solvent only (C). After lysis, HA-Ets-1 was
immunoprecipitated with an anti-HA antibody, and the samples were
subjected to Western blot (WB) analysis to detect the presence of co-
immunoprecipitated ERK5, Ets-1, and ERK2. Blots were stripped to
enable reprobing with another antibody. B, threonine phosphorylation
of Ets-1 in intact cells. As in panel A, except samples were blotted and
probed for the presence of Ets-1 using anti-Ets-1 antibody, stripped,
and probed with an anti-phosphothreonine antibody to determine the
level of Ets-1 phosphorylation (middle band). Results are representa-
tive of three experiments.
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cells revealed that ERK2 interacted with RXR, although this
interaction was not regulated by 1,25D. This specificity of the
MAP kinases for Ets-1 and RXR is in direct contrast to their
lack of specificity toward certain other substrates. For example,
promiscuous substrates such as myelin basic protein and
Sap1a are phosphorylated by ERK1/ERK2, ERK5, and p38 (29,
44). The specificity of a MAP kinase for its target sites can also
be observed between two phosphoacceptor sites within the
same molecule. For example, threonine 82 and serine 260
within RXR are both consensus MAP kinase phosphorylation
sites (40), yet mutating serine 260 to alanine nearly totally
abolished the ability of activated HA-ERK2 to phosphorylate
RXR. This implies that serine 260 in RXR is the preferred
phosphorylation site of ERK1/ERK2. Other examples of speci-
ficity include the recent demonstration that the ERK5-related
kinase p97, but not ERK5, phosphorylates Ets-2 (45), although
Ets-2 is also a substrate for ERK2 (43). Docking domains that
are known to enhance the efficiency of substrate phosphoryla-
tion are likely to play significant roles in determining specific-
ity (46). Analysis of the MAP kinase docking domains on RXR
may provide clues to the reasons for ERK5 not being able to
interact with and phosphorylate RXR as well as why serine
260 is the preferred phosphorylation site for ERK2.
The selective targeting of RXR and Ets-1 by ERK1/ERK2
and ERK5, respectively, implies that the ERKs act via distinct
cis elements and coregulatory complexes on the CYP24 pro-
moter. Consistent with this observation, expression of the dom-
inant-negative MEK5(A) mutant, mutagenesis of threonine 38
to alanine, or the loss of EBS function attenuated CYP24 pro-
moter activity by similar levels. Expression of the serine 260 to
the alanine RXR mutant inhibited 1,25D induction of the
CYP24 promoter, although the magnitude was not as great as
that observed with the expression of the ERK1 dominant-neg-
ative mutant, ERK1K71R, implicating the involvement of
other phosphorylated regulatory proteins. The possibility that
low level phosphorylation of threonine 82 on RXR by ERK1/
ERK2 permitted some induction of the CYP24 promoter activ-
ity was excluded on the basis that mutation of threonine 82 to
alanine did not affect 1,25D-stimulated promoter activity.2
It is evident from the current study that serine 260 on RXR
is a functionally important ERK1/ERK2 phosphorylation site
that facilitates 1,25D induction of the CYP24 promoter in
COS-1 cells. However, this observation is in direct contrast to
Ras-transformed keratinocytes in which phosphorylation of
serine 260 attenuated transactivation by 1,25D and rendered
the cells insensitive to 1,25D-induced apoptosis (40). Moreover,
the 1,25D induction of a transfected VDRE-containing reporter
gene construct in keratinocytes was stimulated by the MAP
kinase inhibitor PD98059 (40). This finding is in marked con-
trast to the inhibitory effect of PD98059 on 1,25D-dependent
induction of the native CYP24 promoter and the artificial
VDRE-driven TK promoter in COS-1 cells. The molecular basis
for this difference in the action of phosphorylated RXR in the
different cell types is not known. Nevertheless, the data imply
that the role(s) played by ERK1/ERK2-phosphorylated RXR
in the actions of 1,25D differs from cell type to cell type. How-
ever, it should be noted that the kinase(s) that phosphorylated
serine 260 in RXR in the keratinocyte study was not identified
(40).
Although the mechanisms by which 1,25D activates the
Ras-MAP kinase pathways are not known, the current studies
establish a critical role for the Ras-ERK1/ERK2-RXR signal-
ing pathway in the induction of the CYP24 promoter by 1,25D.
The Ras-ERK5-Ets-1 pathway plays an enhancing role in pro-
moter activation. Together, these MAP kinases provide a novel
2 P. P. Dwivedi, C. S. T. Hii, A. Ferrante, J. Tan, C. J. Der, J. L.
Omdahl, H. A. Morris, and B. K. May, unpublished data.
FIG. 9. Phosphorylation of Ets-1 by HA-ERK5. A, phosphoryla-
tion of HIS-Ets-1 by HA-ERK5 in a Ras- and ERK5-dependent manner.
COS-1 cells transfected with either HA-ERK2 or HA-ERK5 were stim-
ulated with 1,25D for 5 min (HA-ERK2) or 15 min (HA-ERK5). Some
cells were also co-transfected with either ras17N or MEK5(A). After
lysis, HA-tagged kinase was immunoprecipitated, and kinase activity
was determined using HIS-Ets-1. B, phosphorylation of wild type and
mutant Ets-1, as in panel A but using GST-Ets-1 or GST-Ets-1 T38A as
a substrate. Results are representative of three experiments.
FIG. 10. Proposed model for transcriptional regulation of
CYP24 promoter by 1,25D-mediated nongenomic and genomic
actions in COS-1 cells. We hypothesize that nuclear VDR is also
located at the plasma membrane. The mechanism by which liganded
VDR at the membrane activates ERK1/ERK2 and ERK5 remains to be
established, although Ras is involved possibly through protein kinase C
(PKC) or Src kinase activities. Phosphorylated residues in RXR and
Ets-1 could interact with the coactivators SRC-1 and CREB-binding
protein (CBP), which themselves could be targets of ERK activity.
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mechanism for the induction of CYP24 by facilitating a func-
tional cooperation between the Ets-1 binding site and the prox-
imal vitamin D response element in the presence of 1,25D. The
data in the present study (summarized in Fig. 10) not only
establish a novel role for ERK5 but also provide a stepping
stone for investigating the mechanisms of action for 1,25D in
other hormone-responsive cell types.
The rapid response of 1,25D to activate ERK1/ERK2 and
ERK5 is consistent with nongenomic functions that have been
attributed to several actions of the hormone (22, 23). A key
question in the current study, however, concerns the underly-
ing molecular mechanism by which vitamin D activates MAP
kinase pathways. It can be envisaged that a receptor is located
at the cytoplasmic membrane and is responsible for activation
of signaling molecules (23, 49) as revealed recently for the ER
estrogen receptor and the IGF-1 signal cascade (50). In this
regard, we have recently shown that overexpression of pRSV-
hVDR in COS-1 cells increases vitamin D induction of the
CYP24 promoter and activation of ERK1/ERK2.2 This finding
makes it attractive to suggest that the same isoform of VDR is
present at nuclear and extranuclear locations, as noted in the
schematic for regulation of the CYP24 promoter by 1,25D (Fig.
10). The proposed regulatory scheme also accounts for the
documented regulatory actions of 1,25D in other cellular sys-
tems in which the hormone functions through the protein
kinase C or Src pathways (51, 52). Although the nature of the
cytosolic 1,25D initiation event remains to be determined, it is
apparent that the action of the hormone to regulate CYP24
promoter activity in COS-1 cells is mediated predominately
through a Ras-dependent pathway that involves activation of
ERK1/ERK2 and ERK5 and possibly other undocumented
downstream kinase effectors. Therefore, it is evident from the
current study that the genomic action of 1,25D to control
CYP24 promoter activity is linked tightly to the MAP kinase
pathways and phosphorylation-mediated activation of RXR
and Ets-1, whose regulatory functions are dependent upon
associated coregulatory proteins (47, 48) (Fig. 10).
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